The Biological Therapy Unit is a very new structure within the Spanish and European public health system. It is made up mainly of researchers from Area 3 of the Institute who belong to the Dermatology, Digestive, Rheumatology, Neurology and Hospital Pharmacy Departments.
One of the Unit's objectives is to better select patients who need biological drugs to achieve their rational use in chronic inflammatory diseases by lowering the cost per patient and contributing to system sustainability.
It is funded by the pharmaceutical industry, including: Abbvie Spain S.L.U, Pfizer S.L.U, UCB Pharma S.A., Bristol-MYERS SQUIBB S.A.U., Janssen Cilag, S.A., SANOFI AVENTIS S.A., Fundación Biogen Idec, Merck Sharp & Dohme de España S.A. and Roche Farma S.A.
This unit is independent and any entity or individual can contribute to or take part in it.
The unit is the coordinated application of knowledge about the medical services it incorporates: Rheumatology, Neurology, Dermatology, Neurology and Digestive, Hospital Pharmacy, in order to create a solution that allows the patient to be treated efficiently and at the same time maintain the sustainability of the health system. It is located on the 9th floor of Hospital Universitario de La Princesa.